InvestorsHub Logo
Post# of 253153
Next 10
Followers 840
Posts 120462
Boards Moderated 18
Alias Born 09/05/2002

Re: None

Monday, 05/23/2022 11:40:54 AM

Monday, May 23, 2022 11:40:54 AM

Post# of 253153
PFE/BNTX COVID vaccine—>80% efficacy in young children—(age 6mo-5yr):

https://www.globenewswire.com/news-release/2022/05/23/2448240/0/en/Pfizer-BioNTech-COVID-19-Vaccine-Demonstrates-Strong-Immune-Response-High-Efficacy-and-Favorable-Safety-in-Children-6-Months-to-Under-5-Years-of-Age-Following-Third-Dose.html

The primary endpoint was prevention of symptomatic disease. The regimen tested against placebo consisted of three doses of 3mcg each (9mcg total). By comparison, the regimen of PFE’s vaccine for pre-adolescent older children (age 5-11) is 2 doses of 10mvg each (20mcg total). The adolescent/adult regimen is 2 doses of 30mcg each (60mcg total).

The above are interim data after 10 events (i.e. 10 cases of symptomatic COVID). The trial is slated to have a final analysis after 21 events, but the interim data may be sufficient for an FDA EUA.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.